Status:
COMPLETED
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborating Sponsors:
Centocor, Inc.
Conditions:
Pyoderma Gangrenosum
Crohn's Disease
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous...
Eligibility Criteria
Inclusion
- Must Be ages 18-75
- Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum
- Must never have received Infliximab for the treatment of pyoderma gangrenosum
Exclusion
- Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.
- Have a history of serious infections
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00791557
Start Date
October 1 2008
End Date
February 1 2010
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106